Burning Rock’s Technology
Burning Rock has independently developed a number of industry-leading technologies. Our workflow is adapted to Illumina’s platforms such as NextSeq 2000 and NextSeq 550Dx. The library construction and target enrichment steps feature our proprietary chemistry and we have the unique capability of performing both hybridization-based and amplification-based protocols.
In evaluating the performance of pan-cancer tissue panels, among the 5 vendors that participated in the study including Roche, IDT, Illumina, BR, and Thermo, we are proud our OncoCompass™ Target presented with high sensitivity, specificity and reproducibility, ranking #1 in comprehensive performance.
In evaluating the performance of pan-cancer tissue panels, among the 8 vendors that participated in the study including Agilent, IDT, Illumina, Qiagen, Roche, Thermo, BR, and Genentech, we are proud to consistently place among the leading performers at all dilution ratios. Our assay showed consistent sensitivity over 94%. We ranked #2 in sensitivity and limit of detection.